Immunoglobulin Or Antibody Is Anti-idiotypic Patents (Class 435/327)
-
Patent number: 8969024Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.Type: GrantFiled: August 27, 2008Date of Patent: March 3, 2015Assignee: AbbVie Biotechnology LtdInventors: Zehra Kaymakcalan, Limin Xiong
-
Patent number: 8945528Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.Type: GrantFiled: August 30, 2011Date of Patent: February 3, 2015Assignee: Generon (Shanghai) Corporation Ltd.Inventors: Xiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Yuliang Huang
-
Publication number: 20140242068Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.Type: ApplicationFiled: August 10, 2012Publication date: August 28, 2014Applicant: EMORY UNIVERSITYInventors: Charles A. Parkos, Dominique A. Weber
-
Publication number: 20140134719Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: ApplicationFiled: November 14, 2013Publication date: May 15, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: DIPALI DESHPANDE, GANG CHEN, DARYA BURAKOV, JAMES FANDL, THOMAS ALDRICH, VISHAL KAMAT
-
Publication number: 20140127229Abstract: In certain embodiments, the present invention provides a method of treating an IP-10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.Type: ApplicationFiled: October 16, 2013Publication date: May 8, 2014Inventors: Allison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus
-
Publication number: 20140115729Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: ApplicationFiled: December 20, 2013Publication date: April 24, 2014Applicant: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Patent number: 8697070Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: May 8, 2012Date of Patent: April 15, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20140065164Abstract: In certain embodiments, the present invention provides a method of treating an IP10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IPIO antibody; (b) detecting the level of the anti-IPIO antibody in a sample of the subject; and (c) if the level of the anti-IPIO antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IPIO antibody in the subject such that the IP-10 related disease in the subject is treated.Type: ApplicationFiled: April 27, 2012Publication date: March 6, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Allison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus
-
Patent number: 8617820Abstract: An immunoassay reagent is provided which comprises an analyte binding agent in a diluent, and a glycosaminoglycan in an amount sufficient to reduce non-specific binding in an assay of a sample for the analyte. Provided is such an immunoassay reagent in which the analyte is troponin I, the analyte binding agent is a biotinylated anti-troponin I antibody, and the glycosaminoglycan is chondroitin sulfate. A sample composition is also provided which comprises a sample to be assayed for the presence of an analyte, an analyte binding agent, and a glycosaminoglycan other than heparin. Further provided is a method of detecting an analyte in a sample, in which non-specific binding is reduced in the method using a glycosaminoglycan.Type: GrantFiled: August 28, 2007Date of Patent: December 31, 2013Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Banumathi Sankaran, Sheryl S. Sullivan, Darrell C. Haynes, Philip C. Hosimer, Graham Yearwood
-
Patent number: 8614297Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.Type: GrantFiled: December 15, 2009Date of Patent: December 24, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Essig, Wolfgang Hoesel, Kay-Gunnar Stubenrauch, Rudolf Vogel
-
Publication number: 20130337478Abstract: The present disclosure relates to a method for the purification of a human IgG-CH1 domain comprising molecule using an antigen-binding protein that is capable of binding to an epitope that is comprised in the CH1 domain of each of human IgG1, human IgG2, human IgG3 and human IgG4. The disclosure further relates to the antigen-binding proteins that can be used in the method of the disclosure. The frame-work regions of the antigen-binding proteins of the invention preferably correspond to those of antibodies that naturally are devoid of light chains as may e.g. be found in camelids. The disclosure further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, and to the uses of such immunoadsorbent materials for the purification of IgG-CH1 domain containing molecules from a variety of species.Type: ApplicationFiled: January 31, 2012Publication date: December 19, 2013Applicant: BAC IP B.V.Inventors: Wilhelmus Josephus Johanna Hermans, Sven Blokland, Maria Anna van Kesteren, Johanna Magaretha Horrevoets, Franciscus Johan Marinus Detmers
-
Publication number: 20130315892Abstract: The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.Type: ApplicationFiled: June 7, 2013Publication date: November 28, 2013Inventors: ALESSANDRO MORETTA, ROBERTA CASTRICONI, CHRISTINA BOTTINO, LORENZO MORETTA
-
Patent number: 8563271Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.Type: GrantFiled: August 22, 2012Date of Patent: October 22, 2013Assignee: UCB Manufacturing, Inc.Inventors: David G. Winkler, Jiye Shi, John Latham
-
Publication number: 20130243749Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.Type: ApplicationFiled: June 2, 2011Publication date: September 19, 2013Applicant: Dana Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
-
Patent number: 8420090Abstract: Isolated and/or recombinant adhesin polypeptides from Burkholderia pseudomallei are provided, which are used as vaccines. Genetic constructs comprising nucleic acid sequences encoding such polypeptides are also provided. Vectors comprising such constructs have been prepared and used for transforming host cells for producing the polypeptides of the invention. Antibodies to such polypeptides are also provided. Such antibodies can be used to detect the presence of B. pseudomallei or B. mallei and in methods of treating or preventing Burkholderia infection.Type: GrantFiled: October 4, 2011Date of Patent: April 16, 2013Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of National DefenceInventors: Chad Wesley Stratilo, Scott James Jager
-
Publication number: 20130078234Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.Type: ApplicationFiled: April 24, 2012Publication date: March 28, 2013Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shu Takahashi, Tatsuji Matsuoka, Kenji Murakami, Takeshi Takizawa, Kenji Hirotani, Atsushi Urano, Keisuke Fukuchi, Mitsuhiro Yazawa
-
Publication number: 20130059318Abstract: An object of the present invention is to provide a monoclonal antibody which is effective for diagnosing IgA nephropathy and specifically recognizes and binds to a hinge region of a polypeptide encoded by a heavy chain gene of immunoglobulin A1 that comprises a serine/threonine-linked sugar chain to which galactose is not bound. According to the present invention, it is possible to provide a monoclonal antibody or an antibody fragment thereof that specifically recognizes and binds to a hinge region of a polypeptide encoded by a heavy chain gene of immunoglobulin A1 that comprises a serine/threonine-linked sugar chain to which galactose is not bound, to provide a diagnostic agent using the antibody or the antibody fragment thereof, and to provide a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: December 28, 2010Publication date: March 7, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Etsuji Kaneko, Yuka Sasaki, Katsuhiro Mori, Yutaka Kanda, Mitsuo Satoh
-
Patent number: 8361792Abstract: The invention reflects enhanced antibody expression of an antibody of interest by cell lines transformed by random homozygous gene perturbation methods to either increase or decrease the expression pattern of a gene of the cell line other than the antibody of interest. The transformed cell line exhibits specific productivity rates, SPR, for the RHGP transformed cell liens of 1.5 or more, as compared with the antibody expressing cell line parents prior to transformation by RHGP. A knock out or anti-sense construct may be devised to reduce expression of the target gene, a promoter may be inserter to enhance expression of the target gene. The antibodies expressed by the transformed cell lines exhibit the binding properties of their parent cell lines prior to transformation with RHGP, and increase Total Volumetric Production of said antibody by said cells in a given volume.Type: GrantFiled: May 11, 2010Date of Patent: January 29, 2013Assignee: Functional Genetics, Inc.Inventors: Roxanne Duan, Michael Goldblatt
-
Patent number: 8268617Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: August 26, 2009Date of Patent: September 18, 2012Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20120157663Abstract: The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody.Type: ApplicationFiled: August 24, 2011Publication date: June 21, 2012Inventors: Takachika AZUMA, Hisao TAKIZAWA
-
Publication number: 20120148571Abstract: The present invention relates to amino acid sequences that bind to serum proteins such as serum albumin essentially independently in the pH range of 5 to 8; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.Type: ApplicationFiled: July 18, 2011Publication date: June 14, 2012Applicant: Ablynx N.V.Inventors: Ignace Joseph Isabella Lasters, Hendricus Renerus Jacobus Mattheus Hoogenboom
-
Publication number: 20120141462Abstract: This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such.Type: ApplicationFiled: January 20, 2012Publication date: June 7, 2012Inventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Patent number: 8110190Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.Type: GrantFiled: August 23, 2007Date of Patent: February 7, 2012Inventors: Jean-Guy Gilles, Marc G. Jacquemin, Jean-Marie Saint-Remy, Christian Behrens
-
Patent number: 8058017Abstract: Provided herein are methods and compositions for purifying human factor VIII, human factor VIII-like peptide or fragments thereof. The methods comprise immobilizing a binding molecule for human factor VIII, human factor VIII-like protein or fragments thereof to a solid support, contacting the immobilized binding molecule with a solution containing the human factor VIII, human factor VIII-like protein or fragments thereof, and purifying the factor by separating the solution from the solid support.Type: GrantFiled: January 22, 2010Date of Patent: November 15, 2011Assignee: Dyax Corp.Inventors: Jinan Yu, M. Daniel Potter, Marilous Potter, legal representative, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
-
Publication number: 20110274684Abstract: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc?RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.Type: ApplicationFiled: May 10, 2011Publication date: November 10, 2011Applicant: LFB BIOTECHNOLOGIESInventors: Christian BEHRENS, Christine Gaucher, Christophe De Romeuf
-
Publication number: 20110212085Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung diseases (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.Type: ApplicationFiled: August 19, 2010Publication date: September 1, 2011Applicant: CELERA CORPORATIONInventors: Elizabeth JOSELOFF, Aiqun LI, Tao HE, Steve RUBEN
-
Publication number: 20110165701Abstract: An objective of the present invention is to provide an anti-human IgM monoclonal antibody that is capable of reacting specifically with human IgM and inducing immunoagglutination based on an antigen-antibody reaction with human IgM in solution, and an immunoassay using the said monoclonal antibody. Another objective of the present invention is to provide an agent for suppressing non-specific reactions caused by human IgM that could not be prevented by conventional methods, and an immunoassay in which non-specific reactions caused by human IgM are suppressed. By selecting a monoclonal antibody that reacts with human IgM on the basis of evaluation of reactivity with human IgM in solution, a novel monoclonal antibody capable of agglutinating human IgM by itself and performing a practical immunoagglutination assay has been obtained, and the objectives above have been thus achieved.Type: ApplicationFiled: September 3, 2009Publication date: July 7, 2011Inventors: Yuki Takahashi, Tomo Shimizu, Hiroshi Takahashi, Yasushi Nakamura
-
Publication number: 20110064725Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: March 27, 2009Publication date: March 17, 2011Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
-
Patent number: 7794976Abstract: Recombinant expression vectors are provided comprising a 3?UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.Type: GrantFiled: July 31, 2007Date of Patent: September 14, 2010Assignee: XOMA Technology Ltd.Inventors: Masahisa Handa, Arnold H. Horwitz, Robyn Cotter, Eddie Batista
-
Publication number: 20100074841Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: November 19, 2009Publication date: March 25, 2010Applicant: FACET BIOTECH CORPORATIONInventors: Debbie Law, Kurt C. Gish, Richard Murray, Patricia Culp
-
Publication number: 20100040605Abstract: The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody.Type: ApplicationFiled: May 18, 2009Publication date: February 18, 2010Inventors: Takachika AZUMA, Hisao Takizawa
-
Publication number: 20090285803Abstract: The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory system and various uses of the modulators so identified.Type: ApplicationFiled: May 13, 2009Publication date: November 19, 2009Inventors: Jasvinder Atwal, Marc Tessier-Lavigne, Yan Wu
-
Patent number: 7608453Abstract: A method of identifying at least one consensus sequence for an intracellular antibody (ICS) comprising the steps of: creating a database comprising sequences of validated intracellular antibodies (VIDA database) and aligning the sequences of validated intracellular antibodies according to Kabat; determining the frequency with which a particular amino acid occurs in each of the positions of the aligned antibodies; selecting a frequency threshold value (LP or consensus threshold) in the range from 70% to 100%; identifying the positions of the alignment at which the frequency of a particular amino acid is greater than or equal to the LP value; and identifying the most frequent amino acid, in the position of said alignment.Type: GrantFiled: February 3, 2004Date of Patent: October 27, 2009Inventors: Antonino Cattaneo, Amos Maritan, Michela Visintin, Terrence Rabbitts, Giovanni Settanni
-
Patent number: 7582296Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.Type: GrantFiled: July 28, 2003Date of Patent: September 1, 2009Assignee: D. Collen Research Foundation VZWInventors: Jean Guy G. Gilles, Jean-Marie R. Saint-Remy, Marc G. Jacquemin
-
Publication number: 20090130094Abstract: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc?RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.Type: ApplicationFiled: November 2, 2006Publication date: May 21, 2009Applicant: LFB BIOTECHNOLOGIESInventors: Christian Behrens, Christine Gaucher, Christophe De Romeuf
-
Publication number: 20090068172Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.Type: ApplicationFiled: August 27, 2008Publication date: March 12, 2009Inventors: Zehra Kaymakcalan, Limin Xiong
-
Publication number: 20080160015Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.Type: ApplicationFiled: February 26, 2007Publication date: July 3, 2008Inventors: Jean-Guy Gilles, Marc G. Jacquemin, Jean-Marie Saint-Remy, Christian Behrens
-
Publication number: 20080131881Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.Type: ApplicationFiled: June 27, 2005Publication date: June 5, 2008Inventors: Jack Ladenson, Yvonne Landt, Vijay Modur, Omar Laterza
-
Patent number: 7270961Abstract: The present invention provides methods of quantitating recent secreted antigen specific antibodies from supernatant of antibody secreting cells (ASC) in vitro culture for evaluation of vaccine or antigen induced antigen specific antibody secretion without ex vivo antigen stimulation.Type: GrantFiled: April 11, 2003Date of Patent: September 18, 2007Inventors: Hui Sunny Chang, David Sack
-
Patent number: 7112438Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.Type: GrantFiled: October 15, 2002Date of Patent: September 26, 2006Assignee: Dyax Corp.Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
-
Patent number: 7083943Abstract: The present invention provides a monoclonal and-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 inducts an Immunological response to HMFG in mice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.Type: GrantFiled: December 19, 1996Date of Patent: August 1, 2006Inventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Patent number: 7063845Abstract: The invention is directed to human antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can modulate one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.Type: GrantFiled: April 27, 2001Date of Patent: June 20, 2006Assignees: Gemini Science, Inc., La Jolla Institute for Allergy & ImmunologyInventors: Toshifumi Mikayama, Nobuaki Takahashi, Xingjie Chen, Stephen P. Schoenberger
-
Patent number: 7056702Abstract: The invention provides antibodies reactive with distinct lipocalin epitopes that are useful for detecting inflammation and bacterial infections in mammals.Type: GrantFiled: December 16, 2002Date of Patent: June 6, 2006Inventors: Julie M. Villanueva, Stephen Quirk
-
Patent number: 6949244Abstract: The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.Type: GrantFiled: December 13, 1996Date of Patent: September 27, 2005Assignee: The Board of Trustees of the University of KentuckyInventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Patent number: 6900302Abstract: The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B Streptococcus (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.Type: GrantFiled: November 7, 2003Date of Patent: May 31, 2005Assignee: Chiron S.r.l.Inventors: Giuseppe Teti, Luciano Polonelli
-
Patent number: 6897030Abstract: Immunoassays and antibodies useful in conducting them for human and canine brain natriuretic peptide are described.Type: GrantFiled: July 9, 2001Date of Patent: May 24, 2005Assignee: Scios, Inc.Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
-
Patent number: 6838250Abstract: The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monoclonal antibody populations directed to an antibody that is specific for a high concentration, high molecular weight target antigen.Type: GrantFiled: March 29, 2001Date of Patent: January 4, 2005Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Edward R. Scalice, John L. Daiss
-
Publication number: 20040229310Abstract: The present invention provides methods for producing humanized antibodies and increasing the yield of antibodies and/or antigen binding fragments when produced in cell culture. In one aspect of the invention, at least one framework region amino acid residue of the variable domain is substituted by a corresponding amino acid from a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain. In another aspect, an amino acid is placed at a position proximal to a cys residue that participates in an intrachain variable domain disulfide bond that corresponds to an amino acid found at that position in a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequenc of the variable domain.Type: ApplicationFiled: January 23, 2004Publication date: November 18, 2004Applicant: Genentech, Inc.Inventor: Laura Simmons
-
Patent number: 6812024Abstract: The present invention provides a method of manufacture of an anti-paratopic antibody comprising the steps of: (1) selecting from a pool of antibodies occurring in one species a prototypic set the members of which are effective in binding a specific antigen (or antigen epitope), and (2) utilizing one or more members of said prototypic set, or paratopic fragments thereof, as an immunogen in a host of a different species, or in an in vitro incubation system comprising cells derived from the same or a different species, to produce antibodies having a characteristic which is anti-paratopic with respect to said immunogen to produce a synthetic replicate of the specific antigen or epitope. Antigen (or antigen epitope), and monoclonal antibodies, vaccines and processes of immunization employing the product of the method of manufacture are also described.Type: GrantFiled: August 22, 2001Date of Patent: November 2, 2004Inventor: Roland Keith McGready
-
Publication number: 20040175758Abstract: The present invention provides novel isoforms of the Goodpasture antigen binding protein (GPBP), and related reagents, and also provides methods for isolating and detecting such novel GPBP isoforms. The invention further provides methods identifying compounds to treat one or more of an autoimmune condition and a protein deposit-mediated disorder, as well as novel compounds and methods for treating such conditions and/or disorders.Type: ApplicationFiled: February 5, 2004Publication date: September 9, 2004Applicant: Dr. Juan SausInventors: Juan Saus, Fernando Revert, Francisco Revert-Ros